Publications by authors named "Christopher Heery"

Claim this Profile
C
Constructing the cure: engineering the next wave of antibody and cellular immune therapies.
Stefanie R Bailey, Eric Bartee, Kyle G Daniels, Christopher R Heery, Pravin Kaumaya

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma.
Gregory M Cote, Anthony P Conley, Steven Attia, Brian A Van Tine, Mahesh Seetharam, Christopher Heery

Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab in Patients With Metastatic Colorectal Cancer.
Jason M Redman, Geraldine O'Sullivan Coyne, Clay T Reed, Ravi A Madan, Julius Strauss, Christopher Heery

Oncologist· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor.
Liny John, Hannah Smith, Maran Ilanchezhian, Robin Lockridge, Karlyne M Reilly, Christopher Heery

Pediatr Blood Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Matthew J Frigault, Michael R Bishop, Jacalyn Rosenblatt, Elizabeth K O'Donnell, Noopur Raje, Christopher Heery

Blood Adv· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose fractionation of CAR-T cells. A systematic review of clinical outcomes.
Matthew Frigault, Anand Rotte, Ayub Ansari, Bradford Gliner, Christopher Heery

J Exp Clin Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-response correlation for CAR-T cells: a systematic review of clinical studies.
Anand Rotte, Matthew J Frigault, Ayub Ansari, Brad Gliner, Christopher Heery

J Immunother Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
Peter J DeMaria, Katherine Lee-Wisdom, Renee N Donahue, Ravi A Madan, Fatima Karzai, Christopher Heery

J Immunother Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.
Peter Joseph DeMaria, Marijo Bilusic, Deric M Park, Christopher R Heery, Renee N Donahue

Oncologist· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Julie M Collins, Renee N Donahue, Yo-Ting Tsai, Michell Manu, Claudia Palena, Christopher R Heery

Oncologist· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
Houssein Abdul Sater, Jennifer L Marté, Renee N Donahue, Beatriz Walter-Rodriguez, Christopher R Heery

J Immunother Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Phillip R Pittman, Matthew Hahn, HeeChoon S Lee, Craig Koca, Nathaly Samy, Christopher R Heery

N Engl J Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Arun Rajan, Christopher R Heery, Anish Thomas, Andrew L Mammen, Susan Perry

J Immunother Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
Marijo Bilusic, Christopher R Heery, Julie M Collins, Renee N Donahue, Claudia Palena

J Immunother Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
Margaret E Gatti-Mays, Julius Strauss, Renee N Donahue, Claudia Palena, Jaydira Del Rivero, Christopher R Heery

Clin Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
James L Gulley, Michael Borre, Nicholas J Vogelzang, Siobhan Ng, Neeraj Agarwal, Christopher R Heery

J Clin Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.
Julius Strauss, Christopher R Heery, Joseph W Kim, Caroline Jochems, Renee N Donahue

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
Renee N Donahue, Lauren M Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Christopher R Heery

J Immunother Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
Julius Strauss, Christopher R Heery, Jeffrey Schlom, Ravi A Madan, Liang Cao

Clin Cancer Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
Christopher R Heery, Claudia Palena, Sheri McMahon, Renee N Donahue, Lauren M Lepone

Clin Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Blueprint to Advance Colorectal Cancer Immunotherapies.
Dung T Le, Vanessa M Hubbard-Lucey, Michael A Morse, Christopher R Heery, Andrea Dwyer

Cancer Immunol Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Christopher R Heery, Geraldine O'Sullivan-Coyne, Ravi A Madan, Lisa Cordes, Arun Rajan

Lancet Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.
Christopher R Heery, Ravi A Madan, Mark N Stein, Walter M Stadler, Robert S Di Paola

Oncotarget· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST.
Kathleen E Fenerty, Les R Folio, Nicholas J Patronas, Jennifer L Marté, James L Gulley, Christopher R Heery

BMC Cancer· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
Caroline Jochems, Massimo Fantini, Romaine I Fernando, Anna R Kwilas, Renee N Donahue, Christopher R Heery

Oncotarget· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis